Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 13.38% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTBioAge Labs, Inc.'s latest supported as-filed period reports revenue of $2.5M, 1.6% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 13.38% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -785.80% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 1.62% · CORE
Level · gp.fundamentals.operating_margin
Raw value -1196.78% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 994.08% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 174.17% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -66.4% from the comparable as-filed period.
Debt changed -100.0% from the comparable as-filed period.
Net income changed -21.0% from the comparable as-filed period.
Operating income changed -18.4% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
BIOA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-335407SEC ↗8-KAug 5, 2026Period Aug 5, 20260001193125-26-335368SEC ↗4Jul 1, 2026Period Jun 29, 20260001836297-26-000005SEC ↗4Jun 12, 2026Period Jun 10, 20260001840663-26-000002SEC ↗4Jun 12, 2026Period Jun 10, 20260001771213-26-000004SEC ↗4Jun 12, 2026Period Jun 10, 20260001245624-26-000002SEC ↗4Jun 12, 2026Period Jun 10, 20260001253886-26-000006SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 30, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 4,290 | $11 | $46,547 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 4,000 | $8 | $33,560 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 4,065 | $4 | $17,480 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 7,861 | $4 | $34,431 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed -16979 basis points from the comparable as-filed period.
Research & development changed +22.8% from the comparable as-filed period.
Revenue changed +1.6% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001573785-26-000003| Jun 30, 2026Filed Jul 1, 2026 |
| Barton ShanePrincipal Accounting Officer |
| Open Market SaleDirect |
| 20,216 |
| $25 |
| $509,176 |
| Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 4,290 | $0 | $0 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 4,000 | $0 | $0 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 4,065 | $0 | $0 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 7,861 | $0 | $0 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 9,301 | $11 | $100,916 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 7,261 | $8 | $60,920 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 8,958 | $4 | $38,519 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 14,198 | $4 | $62,187 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Open Market SaleDirect | 42,350 | $25 | $1.1M | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 9,301 | $0 | $0 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 7,261 | $0 | $0 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 8,958 | $0 | $0 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Barton ShanePrincipal Accounting Officer | Option ExerciseDirect | 14,198 | $0 | $0 | Form 4 ↗ |